Process Performance as a Means of Quality Management

Publication
Article
Pharmaceutical TechnologyPharmaceutical Technology, March 2022 Issue
Volume 46
Issue 3
Pages: 28–35

Process performance metrics of eight different mechanical devices were assessed to evaluate compliance with regulatory and compendial criteria.

Alena/Stock.adobe.com – Testing various tablet-splitting devices showed how well they performed according to regulatory and compendial standards.

Alena/Stock.adobe.com

Quality by design (QbD) was an initiative introduced by FDA in 2004 to improve pharmaceutical development and manufacturing. QbD leverages quality tools, such as process performance, that estimate performance during initial setup before a process has been brought to a state of statistical control. By using QbD, pharmaceutical development, and hence manufacturing, becomes a more efficient process. To illustrate the utilization of quality management techniques, process performance will be utilized as an example in the simple process of tablet splitting. Principles and findings can be further extrapolated to more complex processes. For the present study, the process performance metrics of eight different mechanical devices were assessed to evaluate the compliance of these devices with regulatory and compendial criteria. These process performance metrics were used to differentiate the mechanical devices based on their degree of compliance with regulatory and compendial requirements and make recommendations based on values of these metrics, thus increasing process knowledge and understanding.

Click here for a PDF of this article.

Peer-Reviewed

Submitted: Oct. 13, 2021
Accepted: Dec. 6, 2021

About the author

Ammar Khawam, PhD, is a senior managing scientist of product development at Parsolex.

Article Details

Pharmaceutical Technology
Vol. 46, No. 3
March 2022
Pages: 28–35

Citation

When referring to this article, please cite it as A. Khawam, “Process Performance as a Means of Quality Management,” Pharmaceutical Technology, 46 (3) 28–35 (2022).

Recent Videos
Drug Digest: Strategic Partnerships
Roger Viney from ICE Pharma discusses the quality and compliance issues surrounding the use of animal-derived ingredients in the bio/pharma industry.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.
Preeya Beczek from Beczek.COM gives her thoughts on the areas to watch with the new US administration and how Europe might be finalizing preparations for previous legislative changes
Drug Digest: Challenges and Triumphs in Next-Generation Biotherapeutic Development